Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- (-) Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- (-) Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- (-) Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- (-) Value Assessment Methods
Resource Type
Resource Type
Audience
Display Only
Showing 23 Results
Achieving “Fair Access” Requires Better Benefit Design
An Institute for Clinical and Economic Review report acknowledges that patients are still facing barriers to needed treatments as a result of their health benefit design.
NPC Submits Comments on Medicare Physician Fee Schedule Proposed Rule
NPC submitted comments on the Medicare Program’s CY 2022 Physician Fee Schedule proposed rule recommending opportunities to enhance understanding of patient-reported outcomes and address barriers to…
Webcast: Priorities for Patient-Centered Care in Oncology
On a recent webcast, NPC Vice President of Health Services Research Kimberly Westrich discusses the importance of patient-centered care and the benefits and opportunities of incorporating…
NPC’s New Leader: Merging Research and Data with Real-World Experience
NPC Board Chair Michael Ryan says John M. O’Brien’s arrival as the new president and CEO of NPC reinforces a vital role the biopharmaceutical industry can play in the ongoing debate about health care…
NPC Shared Decision-Making and Value-Based Care Research Featured at PQA Annual Meeting
Research conducted by NPC and Discern Health found that shared decision-making and patient decision aid interventions do not always lead to reduced health care costs or utilization.
Patient Voices in Value-Based Cancer Care: Priorities for the Biden Administration
The key to elevating patient voices is using the right tools when developing a value-based payment model: patient-reported measures (PRMs), tools that capture patients’ voices related to their care…
If You Must Do Step Therapy, Do It Right
Finding consensus among health care stakeholders is never easy, and that is certainly true when it comes to the use of care management tools. But there are areas of agreement, especially if we focus…
Empowering the Patient Voice in Value Assessment: Paving the Way for MCDA
The National Health Council (NHC) and National Pharmaceutical Council (NPC) co-hosted a webinar that explored how multi-criteria decision-making analysis (MCDA) can be used in value assessment.
Multi-Criteria Decision Analysis: A Way to Put Patient Concerns Front and Center in Value Assessment?
NHC and NPC released a white paper outlining multi-criteria decision analysis (MCDA), an approach to value assessment that may more holistically address patients’ concerns, experiences and treatment…
AARDA’s Randy Rutta Talks Step Therapy
In this Q&A, Randy Rutta, AARDA’s President and CEO, talks about his organization’s efforts to raise awareness about step therapy and opportunities for patient-centered reforms.
Lessons from COVID-19: Step Therapy Should Not Be a Barrier to Patient Access
Step therapy requires patients to try a clinically recognized, lower cost first-line therapy before receiving reimbursement for an alternative therapy prescribed by the physician and can delay access…
Sustainable Solutions for Patients’ Sake
Blasine Penkowski, Chair of NPC's Board of Directors, proposes some guiding principles on how we can move toward a post-COVID world and build a more resilient system where patients have the care they…
Ready, Fire, Aim: How Not to Approach COVID Pricing Discussions
NPC raises concerns about various approaches to considering pricing for COVID-19 treatments.
NPC Statement on Racial, Social Injustices and Health Disparities
The recent deaths of George Floyd, Ahmaud Arbery and Breonna Taylor have put a spotlight on the racial and social injustices that are unfortunately pervasive in the United States. The COVID-19…
Are Value-based Arrangements the Answer We’ve Been Waiting For?
A study by NPC suggests that while value-based arrangements can be one of many tools that payers leverage to address rising costs, it is also important to recognize the strengths and limitations…
How Do We Place a Value on Indirect Treatment Benefits Like Quality of Life?
A study from NPC and RTI Health Solutions evaluated how institutional barriers prevent the inclusion of broader individual and societal benefits associated with new health care innovations from being…
NPC Weighs in on CMS Oncology Care First Model
NPC submitted comments regarding the Centers for Medicare and Medicaid Services Center for Medicare and Medicaid Innovation informal request for information on the Oncology Care First Model.
NPC and PQA Call for Research Proposals on Barriers to Medication Access
The National Pharmaceutical Council and (NPC) and the Pharmacy Quality Alliance (PQA) announced a new funding opportunity, aimed at supporting research to identify systemic approaches for lowering…
NPC Research Featured in Two Panels on Patient-Reported Measures in Oncology
A white paper by the National Pharmaceutical Council and Discern Health, Improving Patient-reported Measures in Oncology, was highlighted during two recent panels discussing recommendations for…